MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA reports 90.5% interim disease control in NSCLC trials, with Phase 3 enrollment at 65%.

What the company is saying

MAIA Biotechnology is highlighting progress in its clinical pipeline for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). The company emphasizes the completion of enrollment for Part C of its Phase 2 THIO-101 trial and reports a 90.5% interim disease control rate for the combination of ateganosine with cemiplimab in patients who had at least one tumor scan after starting treatment. It frames these efficacy results as nearly triple those of standard chemotherapy, though no direct comparator data is provided. For its pivotal Phase 3 THIO-104 trial, MAIA stresses that 65 patients have been enrolled—65% of its 100-patient year-end target—with dosing ongoing and an interim analysis planned for 2027. The company also points to the FDA Fast Track designation for ateganosine, which could accelerate regulatory review and, if approved, provide five years of marketing exclusivity. CEO Vlad Vitoc, M.D., is quoted to reinforce the company's focus on third-line NSCLC and the potential of ateganosine to address an unmet need. The tone is confident and forward-leaning, with strong emphasis on clinical milestones and regulatory positioning.

What the data suggests

The announcement provides concrete enrollment figures: 150 patients have been treated with ateganosine sequenced with an immune checkpoint inhibitor across Phase 2 and 3 trials. Part C of the Phase 2 THIO-101 trial has completed enrollment, and the interim disease control rate stands at 90.5% among patients evaluable for efficacy. In the pivotal Phase 3 THIO-104 trial, 65 patients are enrolled out of a targeted 100 by year-end 2026, representing 65% progress toward this milestone. The first patient in THIO-104 was dosed in December 2025, and the trial remains on track for an interim analysis in 2027. The FDA Fast Track designation was granted in July 2025, which may expedite regulatory interactions and review. While the 90.5% DCR is a strong interim signal, the claim that efficacy is 'close to triple' standard-of-care chemotherapy is not substantiated with specific comparative data. No safety data, adverse event rates, or financial figures are disclosed. The data is robust for clinical progress but incomplete for a full risk-benefit or financial assessment.

Analysis

The announcement is upbeat, highlighting enrollment milestones and interim efficacy data for ateganosine in NSCLC trials. The 90.5% interim disease control rate is a realised, specific result, and the completion of Part C enrollment in Phase 2 is a concrete milestone. However, several claims are forward-looking, such as the expectation of interim analysis in 2027 and potential FDA approval with exclusivity, which are not imminent. The statement that efficacy is 'close to triple' standard-of-care is not substantiated with comparative data. No financial, cash, or burn rate figures are disclosed, but as a clinical-stage biotech, this is not a deficiency. The tone is moderately promotional, especially in projecting future regulatory and commercial outcomes, but the core clinical progress is real. The gap lies in the extrapolation from interim results to future market impact, which remains unproven.

Risk flags

• ●The pivotal Phase 3 trial (THIO-104) is only 65% enrolled, with final enrollment and dosing targeted for year-end 2026. Delays in recruitment or protocol amendments could push back key milestones and value inflection points.
• ●The 90.5% interim disease control rate is based on an interim analysis in an efficacy-evaluable population, not a final or intent-to-treat analysis. The absence of detailed safety data or adverse event rates means the risk-benefit profile is still uncertain.
• ●The claim that ateganosine's efficacy is 'close to triple' that of standard chemotherapy is not supported by direct comparative data in the release, raising the risk of overstatement and potential disappointment if final results are less favorable.
• ●Regulatory and commercial outcomes remain contingent on future trial success; Fast Track designation expedites review but does not guarantee approval or market adoption.

Bottom line

MAIA Biotechnology has achieved meaningful clinical milestones for ateganosine in NSCLC, with 150 patients treated and a reported 90.5% interim disease control rate in Phase 2. The pivotal Phase 3 trial is 65% enrolled, aiming for full enrollment by year-end 2026 and an interim analysis in 2027, so any regulatory or commercial impact is still at least a year away. While the interim efficacy data are promising, the lack of comparative, safety, and financial disclosures limits the ability to fully assess the risk-benefit and operational trajectory. The Fast Track designation is a positive regulatory signal but does not reduce the inherent uncertainty of late-stage oncology drug development. Investors should focus on completion of Phase 3 enrollment, the quality and durability of final efficacy and safety data, and any updates on regulatory or commercial partnerships as the next critical catalysts. The most important takeaway is that while MAIA's clinical progress is real, the path to approval and commercialization is still long and carries significant execution and data risk.

Announcement summary

(NYSE:MAIA) MAIA Biotechnology, Inc. announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI) in its ongoing Phase 2 and pivotal Phase 3 clinical trials for non-small cell lung cancer (NSCLC). Enrollment is now complete for Part C of the Phase 2 trial, THIO-101, which evaluates ateganosine sequenced with the CPI cemiplimab. MAIA recently reported a 90.5% interim disease control rate (DCR) for the combination therapy in the efficacy evaluable population who had at least one tumor scan after starting treatment. Ateganosine’s efficacy measures are stated to be close to triple the reported outcome for standard-of-care chemotherapy. The pivotal Phase 3 trial, THIO-104, is evaluating ateganosine in sequence with a CPI in third-line (3L) NSCLC patients whose disease has progressed following chemotherapy and CPI treatment. The first patient in THIO-104 was dosed in December 2025, and as of this announcement, 65 patients have been enrolled. The trial is targeting 100 patients enrolled and dosed by year-end 2026. MAIA has reached 65% of its enrollment target for THIO-104 and remains on track to conduct an interim analysis in 2027. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for ateganosine for the treatment of NSCLC in July 2025, which allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. If approved, ateganosine will hold FDA New Chemical Entity (NCE) five-year marketing exclusivity. Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development for NSCLC. The THIO-101 Phase 2 trial is a multicenter, open-label, dose finding study designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition, with primary objectives to evaluate safety, tolerability, and clinical efficacy using Overall Response Rate (ORR) as the primary endpoint. The trial expansion will assess ORR in advanced NSCLC patients receiving third-line therapy who were resistant to previous CPI and chemotherapy. Treatment with ateganosine followed by cemiplimab has shown an acceptable safety profile to date in a heavily pre-treated population. The THIO-104 Phase 3 trial is a multicenter, open-label, randomized study designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in advanced third-line NSCLC, with primary objectives to assess clinical efficacy compared to investigator’s choice of chemotherapy using median Overall Survival (OS) as the primary endpoint, and to evaluate safety and tolerability. ClinicalTrials.gov identifiers for the trials are NCT05208944 (THIO-101) and NCT06908304 (THIO-104).

Disagree with this article?